Trials & Filings

ProMetic Advances Lead Compound into Clinic

PBI-4050 passes fox testing, safe to advance

ProMetic Life Sciences’ lead candidate, PBI-4050, has successfully completed the required GLP toxicology studies performed by a certified CRO confirming that it is safe to advance into clinical trial stages.

Preclinical data on PBI-4050 confirms its potential as a novel therapy to inhibit inflammation and fibrosis which underlies progressive chronic renal diseases and pulmonary fibrosis, as well as fibrosis in other organs such as the liver and the heart. The company plans to commence Phase I trials this year and hopes to begin efficacy trials in 2014.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters